摘要
目的:观察分析磺达肝癸钠用于急性心肌梗死经皮冠状动脉介入术(PCI)术后临床治疗的优势及重要性。方法:选取2008年9月~2010年12月本院住院患者187例,将其随机分为对照组94例和治疗组93例,两组基础治疗相同。对照组除基础治疗外,给予依诺肝素1mg/kg,皮下注射,每12小时1次,连用7d。治疗组给予磺达肝癸钠2.5mg/d皮下注射,每24小时1次,连用7d。观察治疗30d内心脏事件发生情况。结果:治疗组全因死亡例数、再发心绞痛例数均较对照组减少(P<0.05),而再发心肌梗死例数、心脏性死亡例数两组差异无统计学意义。结论:磺达肝癸钠治疗急性心肌梗死PCI术后较依诺肝素安全有效。
Objective:To observe the clinical value and security of acute myocardical infraction percutaneous transluminal coronary intervention(PCI) by using fondaparinux.Methods:187 patients were selected and randomly divided into control group(94 cases) and treatment group(93 cases).Besides the basic treatment,1 mg/kg enoxaparine was administrated to the control group subcutaneously every 12 hours for 7 days.The treatment group were given fondaparinux 2.5 mg per day subcutaneously for 7 days.Occurrences of cardiac disease were observed for 30 days.Results:Occurrences of death,angina of the treatment group were obviously less than the control group(P〈0.05).No obvious difference of re-infarction,cardiac death was found in both groups.Conclusion:Fondaparinux is a safe and effective treatment for AMI percutaneous transluminal coronary intervention.
出处
《中国当代医药》
2011年第20期62-63,共2页
China Modern Medicine
关键词
磺达肝癸钠
急性心肌梗死
PCI术
依诺肝素
Fondaparinux
Acute myocardical infraction
Percutaneous transluminal coronary intervention
Enoxaparine